BioLife Solutions Receives HSR Clearance for Repligen Merger
BLFS sits 96% above its 52-week low of $17.86.
Summary
BioLife Solutions announced that the HSR waiting period for its acquisition by Repligen Corporation has expired, clearing a major regulatory condition for the merger.
Key Events · M&A and Partnerships · BLFS
-
HSR Waiting Period Expired
The Hart-Scott-Rodino Antitrust Improvements Act waiting period for the merger with Repligen Corporation expired on September 3, 2026, satisfying a key regulatory condition.
-
Merger Progress Update
The $1.5 billion cash-and-stock acquisition by Repligen, initially disclosed on July 21, 2026, continues to progress. The transaction remains subject to other customary closing conditions, including BioLife's stockholder approval.
-
Stockholder Vote Scheduled
A special meeting for BioLife stockholders to vote on the adoption of the Merger Agreement is scheduled for October 5, 2026, as previously disclosed.
Analysis · BLFS · Industrial Applications And Services
This filing announces the expiration of the Hart-Scott-Rodino (HSR) waiting period, a critical regulatory milestone for the pending acquisition of BioLife Solutions by Repligen Corporation. The HSR clearance removes a significant antitrust hurdle, increasing the likelihood that the $1.5 billion merger will close as planned. The transaction still requires BioLife stockholder approval, with a vote scheduled for October 5, 2026.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLFS was trading at $34.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $38.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.